People · Operator
Named in public records as an officer, director or promoter · active 2022–2025 · Biotechnology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Newleos Therapeutics, Inc. | — | Biotechnology | Series C | $93.4M | $659.2M | 2025 |
| Carbon Biosciences, Inc. | — | Biotech / Pharma | Series B | $38.0M | $743.9M | 2022 |
Robert Hadfield at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Hadfield on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Steinberg | 1 | 14 |
| Christoph Westphal | 1 | 8 |
| Geeta Vemuri | 1 | 7 |
| Derek Yoon | 1 | 4 |
| Raymond Camahort | 1 | 4 |
| David Donabedian | 1 | 4 |
| Chen Schor | 1 | 4 |
| John McCabe | 1 | 2 |
| John Lawrence | 1 | 1 |
| Ming Cheah | 1 | 1 |
| Robert Kotin | 1 | 1 |
| Jacopo Leonardi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.